 | Up a level |
Tettero, Jesse M; Buisman, Yara; Ngai, Lok Lam; Bachas, Costa; Gjertsen, Bjorn T; Kelder, Angèle; van de Loosdrecht, Arjan A; Manz, Markus G; Pabst, Thomas; Scholten, Willemijn; Ossenkoppele, Gert J; Cloos, Jacqueline; de Leeuw, David C (2023). Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. HemaSphere, 7(12), e981. Wolters Kluwer Health 10.1097/HS9.0000000000000981
Tettero, Jesse M; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J W M; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J M; Löwenberg, Bob; Ossenkoppele, Gert J; Cloos, Jacqueline (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica - the hematology journal, 108(10), pp. 2794-2798. Ferrata-Storti Foundation 10.3324/haematol.2022.282639
Ngai, Lok Lam; Hanekamp, Diana; Janssen, Fleur; Carbaat-Ham, Jannemieke; Hofland, Maaike A M; Fayed, Mona M H E; Kelder, Angèle; Oudshoorn-van Marsbergen, Laura; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Griskevicius, Laimonas; Juliusson, Gunnar; van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; ... (2023). Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood, 141(21), pp. 2657-2661. American Society of Hematology 10.1182/blood.2022019160
Tettero, Jesse M; Al-Badri, Waleed K W; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; van Elssen, Catharina H M J; Fischer, Thomas; Gjertsen, Bjorn T; van Gorkom, Gwendolyn N Y; Gradowska, Patrycja; Greuter, Marjolein J E; Griskevicius, Laimonas; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Löwenberg, Bob; Ossenkoppele, Gert J; ... (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Frontiers in oncology, 12, p. 999822. Frontiers Research Foundation 10.3389/fonc.2022.999822
